# SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

> **NCT05387044** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 28 (estimated)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT05387044
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2023-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387044, "SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05387044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*